Symptom-driven ICS/LABA Therapy for Patients With Asthma Non-adherent to Daily Maintenance Inhalers

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

December 16, 2021

Primary Completion Date

September 30, 2025

Study Completion Date

November 30, 2025

Conditions
AsthmaNonadherence, Medication
Interventions
DRUG

Adherence to symptom driven budesonide/formoterol as compared to adherence to maintenance ICS and symptom-driven SABA

In this study, we propose a pragmatic, pilot, open-label trial where we are comparing adherence to different inhaler regimens. Patients who were previously sub-optimally adherent to maintenance ICS inhalers will either continue receiving maintenance ICS inhalers and symptom-driven SABA inhalers or symptom-driven ICS/LABA inhalers only.

Trial Locations (1)

63110

Washington University in St. Louis School of Medicine, St Louis

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Center for Advancing Translational Sciences (NCATS)

NIH

lead

Washington University School of Medicine

OTHER